ChemoCentryx Inc  

(Public, NASDAQ:CCXI)   Watch this stock  
Find more results for CCXI
4.78
+0.03 (0.63%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.69 - 4.85
52 week 4.09 - 8.25
Open 4.78
Vol / Avg. 53,925.00/89,230.00
Mkt cap 207.17M
P/E     -
Div/yield     -
EPS -0.97
Shares 43.34M
Beta     -
Inst. own 69%
Nov 20, 2014
ChemoCentryx Inc at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 19, 2014
ChemoCentryx Inc at Stifel Healthcare Conference
Nov 5, 2014
Q3 2014 ChemoCentryx Inc Earnings Call
Nov 5, 2014
Q3 2014 ChemoCentryx Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -638.17%
Operating margin - -645.46%
EBITD margin - -635.96%
Return on average assets -33.45% -28.15%
Return on average equity -35.69% -30.25%
Employees 60 -
CDP Score - -

Address

850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�s wholly owned subsidiary is ChemoCentryx Limited.

Officers and directors

Thomas J. Schall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Susan M. Kanaya Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 51
Bio & Compensation  - Reuters
Petrus J. Bekker M.D., Ph.D. Senior Vice President - Clinical and Medical Affairs
Age: 53
Bio & Compensation  - Reuters
Israel F. Charo M.D., Ph.D. Senior Vice President - Research
Bio & Compensation  - Reuters
Markus J. Cappel Ph.D. Chief Business Officer, Treasurer
Age: 53
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Ira Klein M.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Geoffrey M. Parker Independent Director
Age: 49
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 61
Bio & Compensation  - Reuters